검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lymphodepleting chemotherapy (lymphodepleting chemotherapy) Hemogenyx Pharmaceuticals LLC·Non-Hodgkin Lymphoma ORR 80.3% | Fludarabine Phosphate (Fludarabine Phosphate) CTI BioPharma·B-cell Acute Lymphoblastic Leukemi… ORR 59%·t½ 6 h | |
|---|---|---|---|
Overview Program | Zanubrutinib | lymphodepleting chemotherapy | Fludarabine Phosphate |
Overview Company | Juan P. Alderuccio, MD | Hemogenyx Pharmaceuticals LLC | CTI BioPharma |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CNS Lymphoma | Non-Hodgkin Lymphoma | B-cell Acute Lymphoblastic Leukemia |
Overview Indication | CNS Lymphoma | Clear Cell Carcinoma; Phase 1 | Leukemia; Lymphoma |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | ACTIVE | RECRUITING |
MoA Mechanism | inhibits B-cell receptor signaling | CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia | targeted metabolomic profiling of plasma samples was conducted to identify significantly altered metabolites and enriched metabolic pathway |
MoA Biomarker | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | biomarkers exist to predict toxicity risk, underscoring the need for further research | biomarker study in HLA-haploidentical hematopoietic cell transplant recipients |
PK/PD Half-life | — | — | 6 h |
PK/PD Species | Rat | Mouse | Mouse, Human |
PK/PD Animal (cat.) | Rat | Mouse | Human, Mouse |
PK/PD Experiment | PK | PD | PD |
Toxicology Species | Rat | Mouse | Mouse, Human |
Toxicology Animal (cat.) | Rat | Mouse | Human, Mouse |
Toxicology Major finding | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll | Interstitial Lung Disease Associated With Antisynthetase Syndrome |
Toxicology CRS | — | Reported | Reported |
Clinical Primary efficacy | ORR 95.2% | ORR 80.3% | ORR 59% |
Clinical ORR | 95.2% | 80.3% | 59% |
Clinical PFS | 61.4 | 9.03 | — |
Clinical OS | NA | NA | — |
Clinical Result source | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT03483103 | ClinicalTrials.gov NCT00602459 |
Clinical Data Tier / Score | S · 78 | B · 75 | C · 63 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (19일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lymphodepleting chemotherapy (lymphodepleting chemotherapy) Hemogenyx Pharmaceuticals LLC·Non-Hodgkin Lymphoma ORR 80.3% | Fludarabine Phosphate (Fludarabine Phosphate) CTI BioPharma·B-cell Acute Lymphoblastic Leukemi… ORR 59%·t½ 6 h | |
|---|---|---|---|
Overview Program | Zanubrutinib | lymphodepleting chemotherapy | Fludarabine Phosphate |
Overview Company | Juan P. Alderuccio, MD | Hemogenyx Pharmaceuticals LLC | CTI BioPharma |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CNS Lymphoma | Non-Hodgkin Lymphoma | B-cell Acute Lymphoblastic Leukemia |
Overview Indication | CNS Lymphoma | Clear Cell Carcinoma; Phase 1 | Leukemia; Lymphoma |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | ACTIVE | RECRUITING |
MoA Mechanism | inhibits B-cell receptor signaling | CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia | targeted metabolomic profiling of plasma samples was conducted to identify significantly altered metabolites and enriched metabolic pathway |
MoA Biomarker | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | biomarkers exist to predict toxicity risk, underscoring the need for further research | biomarker study in HLA-haploidentical hematopoietic cell transplant recipients |
PK/PD Half-life | — | — | 6 h |
PK/PD Species | Rat | Mouse | Mouse, Human |
PK/PD Animal (cat.) | Rat | Mouse | Human, Mouse |
PK/PD Experiment | PK | PD | PD |
Toxicology Species | Rat | Mouse | Mouse, Human |
Toxicology Animal (cat.) | Rat | Mouse | Human, Mouse |
Toxicology Major finding | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll | Interstitial Lung Disease Associated With Antisynthetase Syndrome |
Toxicology CRS | — | Reported | Reported |
Clinical Primary efficacy | ORR 95.2% | ORR 80.3% | ORR 59% |
Clinical ORR | 95.2% | 80.3% | 59% |
Clinical PFS | 61.4 | 9.03 | — |
Clinical OS | NA | NA | — |
Clinical Result source | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT03483103 | ClinicalTrials.gov NCT00602459 |
Clinical Data Tier / Score | S · 78 | B · 75 | C · 63 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (19일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교